The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances for both compounds.
Full Title of Study: “Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 2008
Salbutamol (VentolinTM) is a short acting beta agonist (SABA) which is used to treat wheezing, dyspnea and breathing difficulties caused by asthma and COPD. Further, it is also used to prevent bronchospasm during exercise.
Ipratropium bromide (Atrovent® HFA) is a short acting anticholinergic bronchodilator (short acting muscarinic antagonist (SAMA)) that improves lung function, dyspnea, exercise tolerance and health-related quality of life in patients with COPD. Studies have also shown that ipratropium bromide might reduce COPD exacerbations and related hospitalisations because the extended bronchodilatation might reduce infection rates by improving clearance of respiratory secretions.
In this open, randomized, two-way crossover, pilot study the effect of salbutamol in patients with moderate and severe COPD will be examined in comparison with the effects of ipratropium bromide. These patients will receive 400 µg salbutamol and 80 µg ipratropium bromide in a randomized crossover design.
The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric indices (as Forced Expiratory Volume in one second (FEV1) and Tiffeneau index) with the Computational Fluid Dynamics (CFD) based calculated airway volumes and resistances for both compounds.
- Drug: Salbutamol
- 400 µg inhalation once
- Drug: ipratropium bromide
- 80 µg inhalation once
Arms, Groups and Cohorts
- Active Comparator: salbutamol
- 6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
- Active Comparator: ipratropium bromide
- COPD patients GOLD stage II and III
Clinical Trial Outcome Measures
- The primary objective of this study is to assess the effect of a single dose of salbutamol in comparison with ipratropium bromide on central and peripheral small airways with high-resolution/multislice CT scan imaging technique.
- Time Frame: 1 month
- The secondary objectives are to evaluate effects on spirometric indices to correlate these with the CFD based calculated airway volumes and resistances for both compounds and to evaluate the safety of the products.
- Time Frame: 1 month
Participating in This Clinical Trial
1. Patients with documented COPD based on the following criteria:
- Smoking history of at least 10 pack-years.
- Decreased Tiffeneau index (FEV1/(F)VC < 0.70).
2. Patients aged ≥ 40 years.
3. Patients should present moderate to severe COPD with an FEV1 between 30 and 80% of predicted (GOLD 2 and 3).
4. Patients should be treated according to GOLD guidelines.
5. Able to inhale study drug.
6. Maintained on stable respiratory medications for 6 weeks prior to visit 1.
7. Able to perform lung function tests.
8. Able to follow study procedures.
1. Patients who are allergic to salbutamol, ipratropium bromide or to another element of the product.
2. Patients allergic to sojalecithin and products on the basis of soja and peanut.
3. Patients who have or ever had glaucoma.
4. Patients with urinary problems, prostate hyperplasy or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.
5. Patients with a recent history (i.e. six months or less) of myocardial infarction.
6. Patients with any unstable or life threatening cardiac arrhythmia.
7. Patients with severe kidney insufficiency (creatinine clearance ≤50 ml/min)a.
8. Patients below the age of 40.
9. Patients who are pregnant or are breast-feeding.
10. Patients who are treated with other anticholinergic medications, that cannot be stopped during the study period.
11. A respiratory infection or exacerbation of COPD in the four weeks prior to screening.
12. Significant alcohol or drug abuse within the past 12 months.
13. Participation in another trial with an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
14. Known active tuberculosis.
15. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.
16. A history of thoracotomy with pulmonary resection.
17. Active or untreated malignancy.
18. Use of oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at doses ≥ 10 mg/day.
a Cockroft's formulae should be applied: in male: creatinine clearance = (140-age) x weight / 72 x creatininemia in female: creatinine clearance = 0.85 x (140-age) x weight / 72 x creatininemia
Gender Eligibility: All
Minimum Age: 40 Years
Maximum Age: 85 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- University Hospital, Antwerp
- Provider of Information About this Clinical Study
- Prof Wilfried De Backer, Antwerp University Hospital
- Overall Official(s)
- Wilfried A De Backer, MD PhD, Principal Investigator, University Hospital, Antwerp
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.